- Market Research
- Ineffective Esophageal Motility Treatment Market is Segmented by Devices such as Reflux Management Systems, Endoscopic Pain Modulators, Endostaplers Radiofrequency (RF) Ablation Devices, Myotomy Devices having Drugs such as H2 Receptor Antagonists, Antacids Proton Pump Inhibitors, Dopamine Antagonists, Prokinetic Agents, Calcium Channel Blockers
The recent past has observed soaring preference for device-based treatment, as minimally-invasive and non-invasive options flood the market. Surgical treatment of ineffective esophageal motility follows the minimally-invasive approach, involving fundoplication devices and reflux management systems.
Advancements in technology have taken place, such as radiofrequency stimulation to lower esophageal sphincter (LES) muscles, and RF energy remodelling the tissue, recreating the barrier function. Such technologically advanced treatment solutions are anticipated to propel the demand for ineffective esophageal motility treatment devices.
On the contrary, drug-based treatment with PPIs and antacids is the first line of therapy adopted by physician for the treatment of GERD, heartburn, and burning chest pain. Higher adoption of drug-based treatment is anticipated to drive the growth of the ineffective esophageal motility treatment market.
However, advantages in terms of precision in treatment is being emphasized as the key factor that will boost the demand for device-based ineffective esophageal motility treatment in the near future. For instance, in 2017, spending of the Canadian government for PPIs in public drug programs was close to US$ 198 Mn.
Find Out More about the Report Coverage
- Johnson & Johnson
- Mylan Pharmaceutical
- MediGus Ltd.
- Torax Medical
- Medtronic plc.
- AstraZeneca plc.
- Teva Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- GlaxoSmithKline plc.
- Bayer AG
- Pfizer Inc.
- Bausch Health Companies Inc.
- Mederi Therapeutics, Inc.
- Becton, Dickinson and Company (C. R. Bard, Inc.)
- EndoGastric Solutions, Inc
Sedentary Lifestyle & Obesity Driving GERD Patient Pool - Key Market Driver
Increasing prevalence of gastroesophageal reflux disease is one of the most important factors that is responsible for the growth of the ineffective esophageal motility treatment market. Gastroesophageal reflux disease (GERD) is the most prevalent gastrointestinal disease in the U.S., as the prevalence of obesity is very high in the country.
Factors increasing the complications of GERD include advanced age, increased tobacco use, and abdominal obesity. According to the World Gastroenterology Organization (WGO), the prevalence of gastroesophageal reflux disease is increasing throughout the world.
There are reported differences in the prevalence of gastroesophageal reflux disease, ranging from 2.5% to 6.6% in Asia to up to 13.8% to 25.8% in North America. Increasing prevalence of gastroesophageal reflux disease is correlated with the increasing prevalence of obesity in several countries, as well as poor diet and poor lifestyle factors.
Higher rate of comorbidities resulting in GERD and heartburn are anticipated to propel the ineffective esophageal motility treatment market size through 2030.
Customize this Report
Explore Intelligence Tailored to Your Business Goals.
Advancements in Ineffective Esophageal Motility Treatment to Fuel Market Growth
GERD is one of the most prevalent gastrointestinal disorders in the U.S. It can lead to substantial morbidity; however, in very rare cases, it results in mortality. Risk factors include old age, sedentary lifestyle, tobacco usage, and excessive abdominal fat. Males as well as females suffer from GERD; however, the prevalence of this disease is found to be higher in males.
The prevalence of gastroesophageal disorders generally increases with age, particularly after the age of 40. A clear shift towards OTC and generic formulations from branded drugs has been observed in the past, on account of patent expiry of popular of blockbuster drugs in the gastric motility disorder treatment market.
Ease of manufacturing, availability of low-cost raw materials, and lower price point are aiding the rapid market entry of generic PPI and antacid drugs in lower income countries. These ineffective esophageal motility treatment market trends are anticipated to aid market growth over the coming years.
For instance, a generic version of Prilosec (AstraZeneca plc.) was launched by Lupin Pharmaceuticals, Inc. (2015) and Glenmark Pharmaceuticals (2014).
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
Regional Analysis of Ineffective Esophageal Motility Treatment Market
Sales of drugs and device-based ineffective esophageal motility treatment are growing in developing regions. Increasing prevalence of dysphagia, GERD, achalasia, and burning chest pain across East Asia and South Asia, with higher volumes of comorbidities in the region, are propelling the demand for ineffective esophageal motility treatment devices.
While cost assistances importantly account for the increasing popularity of ineffective esophageal motility treatment across emerging and developing markets, a consistent rise in the number of healthcare facilities involving use of low-cost medication and minimally-invasive surgical treatment options is anticipated to drive the sales of ineffective esophageal motility treatment in the near future.
However, the high cost of treatment devices and lower reimbursement rates may remain as a key restraining factor for the growth of the ineffective esophageal motility treatment market during the forecast period.
Explore Persistence Market Research’s expertise in promulgation of the business !
COVID-19 Impact on Ineffective Esophageal Motility Treatment Market
Lockdowns and restricted travel have affected almost all countries around the world, due to the COVID-10 outbreak. This has affected most sectors, and the ineffective esophageal motility treatment market is bearing the brunt too. For now, amidst the pandemic, it is understandable that healthcare priorities have changed at hospitals and healthcare centers.
Reduced visits by patients needing ineffective esophageal motility treatment will restrict market growth in the near-term. Also, raw material procurement issues and drug shortages are adding to the current crisis situation.
A detailed analysis of the ineffective esophageal motility treatment market has brought our analysts to a conclusion that, this industry is still in the stage of infancy, and has significant growth prospects subject to the minimalistic nature of treatment devices. Drug-based treatment has evolved, owing to advanced PPI and prokinetic agents. The large patient pool and affordable treatment options are is anticipated to offer a lucrative landscape for key market players. North America and Europe dominate the global ineffective esophageal motility treatment market, owning to wider adoption of ineffective esophageal motility treatment drugs and preference for new treatment devices in operative procedures.
Key Segments of Ineffective Esophageal Motility Treatment Market
PMR’s study on the ineffective esophageal motility treatment market offers information divided into four important segments — product, indication, end user, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Key Questions Answered in PMR’s Ineffective Esophageal Motility Treatment Market Report
- Which regions will continue to remain the most profitable regional markets for ineffective esophageal motility treatment market players?
- Which factors will induce a change in the demand for ineffective esophageal motility treatment during the assessment period?
- How will changing trends impact the ineffective esophageal motility treatment market?
- How can market players capture the low-hanging opportunities in the ineffective esophageal motility treatment in developed regions?
- What are the winning strategies of stakeholders in the ineffective esophageal motility treatment market to upscale their position in this landscape?
- What are the restraints that investors need to be aware of and might tackle while investing in the ineffective esophageal motility treatment market?
- What are the developmental trends in ineffective esophageal motility treatment sectors that will impact the market?
- How can businesses in the ineffective esophageal motility treatment market avail the growth opportunities in developed and emerging sectors?